SABCS: Risk-Reducing Surgery Improves Outcomes in Young Breast Cancer Patients With BRCA Mutations
By Lori Solomon HealthDay Reporter
MONDAY, Dec. 16, 2024 -- Risk-reducing mastectomy (RRM) and salpingo-oophorectomy (RRSO) are both associated with significant improvements in outcomes among young BRCA carriers with breast cancer, according to a study presented at the annual San Antonio Breast Cancer Symposium, held from Dec. 10 to 13 in San Antonio.
Matteo Lambertini, M.D., Ph.D., from the University of Genova-IRCCS Policlinico San Martino Hospital in Genoa, Italy, and colleagues investigated the association between RRM and/or RRSO and survival outcomes among young BRCA carriers with breast cancer. The analysis included 5,292 women with germline BRCA1 and/or BRCA2 pathogenic variants diagnosed with stage I to III invasive breast cancer at 40 years of age or younger (2000 through 2020).
The researchers found that during a median follow-up of 8.2 years, RRM and RRSO were both associated with improved outcomes. Patients who underwent RRM had a 35 percent lower risk for death and a 42 percent lower risk for breast cancer recurrence or second primary malignancy, while those who underwent RRSO had a 42 percent lower risk for death and a 32 percent lower risk for breast cancer recurrence or second primary malignancy. For RRM, improved outcomes were seen whether or not the germline BRCA mutation was present in the BRCA1 or BRCA2 gene; however, for RRSO, overall survival varied, with a greater survival benefit seen for patients with germline mutations in BRCA1 than in BRCA2 (56 and 15 percent lower risk for death, respectively). For patients undergoing RRSO, the greatest survival benefits were seen for triple-negative and hormone receptor-positive breast cancers (56 and 20 percent lower risk for death, respectively). Among patients who underwent both surgeries and those who had only one surgery, overall survival was similar.
"These findings are critical for improving the counseling of young BRCA carriers with breast cancer on cancer risk management strategies," the authors write.
One author disclosed ties to the pharmaceutical industry.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted December 2024
Read this next
One-Week Radiotherapy for Breast Cancer Safe, Effective Up to 10 Years
TUESDAY, May 27, 2025 -- A five-fraction, one-week schedule of adjuvant breast radiotherapy is as safe and effective as a standard three-week schedule for patients with invasive...
Artificial Intelligence Flags Interval Breast Cancers Visible at Screening
FRIDAY, May 23, 2025 -- Artificial intelligence (AI) more often flags and accurately localizes interval breast cancers (IBCs) that are visible at screening than true interval or...
Abbreviated Breast MRI Has High Diagnostic Accuracy for Dense Breasts
THURSDAY, May 22, 2025 -- For women with extremely dense breasts who are negative for cancer at mammography, abbreviated breast magnetic resonance imaging (MRI) for first-round...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.